Format: Online Course
Credit: 2.0 AMA PRA Category 1
Credit: No ARRT credit available as of 10/1/2014
Fee for Credit Certificate: $0
- Click ENROLL NOW to register for this program
Extracellular and Hepatobiliary MRI Contrast Agents
in the Evaluation of Liver Disease
An accredited program for radiologists, advanced-level radiologic technologists, hepatologists, liver surgeons, and other healthcare providers involved in the diagnosis and management of patients with liver disease.
Liver disease is common and encompasses a range of benign and malignant entities. Medical imaging with a variety of modalities is often critical for the diagnosis and management of hepatobiliary diseases and is critical for transplant patients. Contrast-enhanced magnetic resonance imaging (MRI) has the capability to both detect and characterize many focal and diffuse diseases of the liver and bile ducts and is assuming a greater role in the diagnosis and management of liver disease.
The goal of this activity is to examine the use of extracellular and hepatobiliary gadolinium-based contrast agents in the evaluation of liver disease with magnetic resonance imaging. This comprehensive presentation will review timing and signal intensity enhancement patterns associated with vascular phase imaging, compare the appearance of liver lesions using extracellular and hepatobiliary gadolinium-based contrast agents, discuss the importance of hepatocyte phase imaging, and examine the challenges and pitfalls of contrast-enhanced liver MR imaging.
At the conclusion of this activity, participants should be more confident to:
- Compare the differences between extracellular and hepatobiliary gadolinium-based contrast agents for MR imaging the liver
- Describe the timing and signal intensity enhancement patterns related to the hepatic arterial phase, portal venous phase, equilibrium phase, and hepatocyte phase imaging
- Associate vascular patterns of benign and malignant liver disease to inform the differential diagnosis
- Explain the importance of the hepatocyte phase and biliary enhancement seen with hepatobiliary contrast
- Recognize the advantages and limitations of extracellular and hepatobiliary gadolinium-based for MR imaging the liver
Accreditation and Credit
International Center for Postgraduate Medical Education (ICPME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
ICPME designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- Click on the "ENROLL NOW" and follow the instructions to enroll in this course online.
- The course will be accessible from your "MY ACCOUNT" page.
Your online account with ICPME serves as a permanent record of credit certificates earned through www.icpme.us
- Log-in to your account at www.icpme.us
- View the entire one-hour session. The question-and-answer period at the end of the lecture is not required to receive credit.
- At the conclusion of the lecture, close the WebEx Player window. You will be redirected to the ICPME website.
- From the COURSE HOME page, click the buttons for POSTTEST and for EVALUATION.
- A passing grade of at least 75% is required to receive credit. You may take the test up to three times.
- Upon receipt of a passing grade, you will be able to print a certificate of credit from your account on www.icpme.us
Claude B. Sirlin, MD is associate Professor in Residence, Department of Radiology, University of California, San Diego; Chief of Body MRI, Director of Liver Imaging Research Group, University of California Medical Center, San Diego. He completed diagnostic radiology residency at the University of California, San Diego, and fellowship training in cross-sectional body imaging at Stanford University.
Irene Cruite, MD is a research fellow with the Liver Imaging Research Group, University of California, San Diego. She completed diagnostic radiology residency at the Royal College of Surgeons in Ireland. Dr. Cruite’s clinical interests include cross-sectional body imaging, with particular interest in liver imaging.
It is the policy of ICPME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with the ICPME Policy on Resolution of Conflicts of Interest, faculty, advisors, planners, and managers who are in a position to control the content of CME activities are asked to disclose any relationships with companies whose products or services may relate to the content of this presentation, as well as off-label or unapproved use of commercial products and/or devices.
Faculty, advisors, planners, and managers have reported the following relationships with commercial interests related to the content of this CME activity:
Claude B. Sirlin, MD has received grants for clinical research from GE Healthcare Biosciences Division, Bayer HealthCare Pharmaceuticals, and Bracco. He has served as a speaker or a member of a speakers bureau for Bayer HealthCare Pharmaceuticals.
Irene Cruite, MD has received fees for educational services from Bayer HealthCare Pharmaceuticals and Bracco.
Advisors, Planners, and Managers
John R. Leyendecker, MD has received funding for contracted research from Bracco and has received royalties and fees for non-CME services from Bayer HealthCare Pharmaceuticals and Bracco.
Elmar M. Merkle, MD has received consulting fees from Bayer HealthCare Pharmaceuticals and fees for non-CME services from Bayer HealthCare Pharmaceuticals and Siemens.
Frank H. Miller, MD has no relevant conflicts to report.
Scott B. Reeder, MD, PhD has received consulting fees from Bayer HealthCare Pharmaceuticals.
Vickie Phoenix has no relevant conflicts.
This activity includes discussion of the off-label use of MR contrast for liver, vascular, and biliary imaging.
For questions regarding this program, please contact ICPME:
Phone: 607-257-5860 x 10